



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/069,605	02/26/2002	Keith M Skubitz	09531-203US1	3442
26191	7590	11/21/2007		EXAMINER
FISH & RICHARDSON P.C. PO BOX 1022 MINNEAPOLIS, MN 55440-1022				EMCH, GREGORY S
			ART UNIT	PAPER NUMBER
			1649	
			MAIL DATE	DELIVERY MODE
			11/21/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/069,605	SKUBITZ ET AL.
	Examiner	Art Unit
	Gregory S. Emch	1649

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 07 September 2007.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1,2,5-10,19-22 and 27-31 is/are pending in the application.

4a) Of the above claim(s) 19-22 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1,2,5-10 and 27-31 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) 1,2,5-10,19-22 and 27-31 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____.

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.

5) Notice of Informal Patent Application
 6) Other: _____.

DETAILED ACTION

Response to Amendment

Claims 3, 4, 11-18, 23-26 and 32-45 have been canceled and claims 1, 2, 19, 20, 27 and 28 have been amended as requested in the amendment filed on 07 September 2007. Following the amendment, claims 1, 2, 5-10, 19-22 and 27-31 are pending in the instant application.

Claims 19-22 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Claims 1, 2, 5-10 and 27-31 are under examination in the instant office action.

Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicants' response and withdrawn.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated

by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

The provisional rejection of claims 1, 2, 5-10 and 27-31 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-34 and 38-40 of copending application no. 10/469,273 is maintained for reasons of record and as set forth below.

In the reply filed on 07 September 2007, Applicants "respectfully request that this rejection be held in abeyance until allowable subject matter is identified. As that time, provided the non-statutory obviousness-type double patenting rejection still applies, Applicants will submit an appropriate Terminal Disclaimer."

However, until such a time occurs, the rejection is maintained.

Claim Rejections - 35 USC § 112, first paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of claims 1, 2, 5-10 and 27-31 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is maintained for reasons of record and as set forth below. The claim contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

In the reply filed on 07 September 2007, Applicants state, "Applicants have amended claims 1 and 27 to refer to a 'biologically active' analog and also to require that the peptide or analog 'decrease homotypic adhesion among CD66a family members'...In view of the amendments herein, the pending claims have adequate written description support in the specification."

Applicants' arguments have been fully considered and are not found persuasive.

Applicants argue that the specification contains an adequate written description of the claimed subject matter because the claims contain a function (decreases homotypic adhesion among CD66a family members) and a structural limitation (analog of SEQ ID NO: 14). However, in the University of California v. Eli Lilly and Co., 43

USPQ2d 1398 (Fed. Cir. 1997), the court held that one of two elements may satisfy a genus of cDNAs: i) a representative number of cDNAs, defined by nucleotide sequence, falling within the scope of the genus or; ii) a recitation of structural features common to members of the genus, which features constitute a substantial portion of the genus.). In the instant case, the first element is not met because only a cDNA encoding SEQ ID NO: 14 is disclosed. The second element requires structural features common to members of the genus. However, in the instant disclosure, insufficient guidance is provided as to which are the critical residues that are necessary for the claimed peptide function of decreasing homotypic adhesion among CD66a family members.

In the instant case, with the exception of SEQ ID NO: 14, the skilled artisan cannot envision the detailed chemical structure of the encompassed polypeptides, and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of isolating it. The compound itself is required. See *Fiers v. Revel*, 25 USPQ2d 1601 at 1606 (CAFC 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016.

Therefore, only isolated peptides comprising the full-length, unaltered amino acid sequences set forth in SEQ ID NO: 14, but not the full breadth of the claims meets the written description provision of 35 U.S.C. §112, first paragraph. Applicants are reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

The scope of enablement rejection of claims 1, 2, 5-10 and 27-31 under 35 U.S.C. 112, first paragraph, is maintained for reasons of record and as set forth below. This is because the specification, while being enabling for peptides of SEQ ID NO: 14 and methods thereof, does not reasonably provide enablement for peptides and biologically active analogs of SEQ ID NO: 14 and methods thereof. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure would require undue experimentation include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art and, (8) the breadth of the claims. *In re Wands*, 8 USPQ2d, 1400 (CAFC 1988).

In the reply filed on 07 September 2007, Applicants state, "Applicants have amended claims 1 and 27 to refer to a 'biologically active' analog and also to require that the peptide or analog 'decrease homotypic adhesion among CD66a family members'."

Applicants' arguments have been fully considered and are not found persuasive.

The instant claims require the use of a broad genus of peptides and as stated above, Applicants have not described all of the common features of the genus such that the skilled artisan could identify individual members. The potential amino acid

sequences encompassed by the claim have particular structures, the predictability of which is complex and outside the realm of routine experimentation. Since detailed information regarding the structural requirements of the multitude of potential amino acid sequences encompassed by the claims are lacking, and given the lack of working examples reciting any and all of the sequences encompassed by the claims, it is unpredictable as to which variations, if any, meet the limitations of the claims. Thus, making said peptides or polypeptides and testing them for the claimed biological activity would constitute undue experimentation.

Relevant art regarding biliary glycoprotein (BGP; i.e., an amino acid molecule comprising SEQ ID NO: 14) and BGP splice variants often have divergent functions. Specifically, Barnett et al (Mol. Cell. Biol. 13: 1273-1282, 1993) teaches that BGP isoforms probably have diverse *in vivo* functions and that fusions comprising the extracellular domain of BGPa and an Fc immunoglobulin fragment and a BGPb-Fc have different functions (p.1280, ¶ 2 and 3). Thus, the predictability of amino acid sequences that would function as claimed is complex and outside the realm of routine experimentation.

The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue. Due to the large quantity of experimentation necessary to practice the claimed invention, the absence of working examples directed to same, the complex nature of the invention, the state of the prior art which establishes the unpredictability of the claimed methods, and the breadth of the

claims which encompass variant proteins, undue experimentation would be required of the skilled artisan to practice the claimed invention in its full scope.

Conclusion

No claims are allowed.

THIS ACTION IS MADE FINAL. Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gregory S. Emch whose telephone number is (571) 272-8149. The examiner can normally be reached 9:00 am - 5:30 pm EST (M-F).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey J. Stucker can be reached at (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gregory S. Emch/

Gregory S. Emch, Ph.D.
Patent Examiner
Art Unit 1649
15 November 2007

/Elizabeth C. Kemmerer/
Primary Examiner, Art Unit 1646